Medigen Vaccine Biologics : Clarification on 2022/02/16 media reports

Close

Today's Information

Provided by: Medigen Vaccine Biologics Corporation
SEQ_NO	2	Date of announcement	2022/02/16	Time of announcement	14:01:55
Subject	Clarification on 2022/02/16 media reports
Date of events	2022/02/16	To which item it meets	paragraph 53
Statement	1.Date of occurrence of the event:2022/02/16 2.Company name: Medigen Vaccine Biologics Corp. 3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office 4.Reciprocal shareholding ratios:N/A 5.Name of the reporting media:Economic Daily News 2022/02/16 C04 6.Content of the report:Charles Chen, the President of MVC (6547) said yesterday (02/15), MVC is also conducting the immuno-bridging phase 3 clinical trial in EU. The result is also expected to be released in the 2nd quarter of 2022. 7.Cause of occurrence: After consultation with European Medicines Agency (EMA) and considering the difficulty of recruiting subjects due to high vaccine coverage rate in EU, MVC will submit the clinical trial results conducted in non-EU country to EMA for review. If there is a specific progress, it will be announced in accordance with the regulations. 8.Countermeasures:None 9.Any other matters that need to be specified: New drug development requires long process, vast investments and with no guarantee in success which may pose investment risks. The investors are advised to exercise caution and conduct thorough evaluation.